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Background: We present a method that utilizes DNA methylation profiling for prediction of the cytogenetic
subtypes of acute lymphoblastic leukemia (ALL) cells from pediatric ALL patients. The primary aim of our study was
to improve risk stratification of ALL patients into treatment groups using DNA methylation as a complement to
current diagnostic methods. A secondary aim was to gain insight into the functional role of DNA methylation in ALL.
Results: We used the methylation status of ~450,000 CpG sites in 546 well-characterized patients with T-ALL or
seven recurrent B-cell precursor ALL subtypes to design and validate sensitive and accurate DNA methylation classifiers.
After repeated cross-validation, a final classifier was derived that consisted of only 246 CpG sites. The mean sensitivity
and specificity of the classifier across the known subtypes was 0.90 and 0.99, respectively. We then used DNA
methylation classification to screen for subtype membership of 210 patients with undefined karyotype (normal or
no result) or non-recurrent cytogenetic aberrations (‘other’ subtype). Nearly half (n = 106) of the patients lacking
cytogenetic subgrouping displayed highly similar methylation profiles as the patients in the known recurrent
groups. We verified the subtype of 20% of the newly classified patients by examination of diagnostic karyotypes,
array-based copy number analysis, and detection of fusion genes by quantitative polymerase chain reaction (PCR)
and RNA-sequencing (RNA-seq). Using RNA-seq data from ALL patients where cytogenetic subtype and DNA
methylation classification did not agree, we discovered several novel fusion genes involving ETV6, RUNX1, and PAX5.
Conclusions: Our findings indicate that DNA methylation profiling contributes to the clarification of the heterogeneity
in cytogenetically undefined ALL patient groups and could be implemented as a complementary method for
diagnosis of ALL. The results of our study provide clues to the origin and development of leukemic transformation.
The methylation status of the CpG sites constituting the classifiers also highlight relevant biological characteristics in
otherwise unclassified ALL patients.
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Table 1 Summary of ALL samples with known subtype
used to design DNA methylation-based classifiers
Immuno-phenotype Cytogenetic abnormality Fusion gene N
T-ALL Various Various 101
BCP ALL HeH - 189
t(12;21) EVT6/RUNX1 161
11q23/MLL MLL-r 27
t(1;19) TCF3/PBX1 21
dic(9;20) - 20
t(9;22) BCR/ABL1 19
iAMP21 - 8
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The genetic subtypes of pediatric acute lymphoblastic
leukemia (ALL) are characterized by large-scale chromo-
somal aberrations, such as aneuploidies and transloca-
tions [1-3]. Karyotyping, fluorescent in situ hybridization
(FISH), reverse transcriptase polymerase chain reaction
(RT-PCR), and array-based methods for copy number
analysis are routinely used to detect high hyperdiploidy
(HeH, 51-67 chromosomes), the translocations t(9;22)
(q34;q11)[BCR/ABL1], t(12;21)(p13;q22)[ETV6/RUNX1],
t(1;19)(q23;p13.3)[TCF3/PBX1], 11q23/MLL-rearrange-
ment, dic(9;20)(p13.2;q11.2), and intrachromosomal
amplification of chromosome 21 iAMP21[RUNX1 X >3],
which are recurrent in patients with ALL. Therapy inten-
sity for ALL patients is determined by risk assessment
based on presenting features, such as white blood cell
count, B- or T-lineage, genetic aberrations, and minimal
residual disease after induction treatment [4,5]. The accur-
acy of detecting chromosomal abnormalities by karyotyp-
ing, FISH, and PCR is generally high; however, these
methods do not allow detection of all the aberrations that
may occur [6]. Moreover, 15% of ALL patients harbor
complex, non-recurrent genomic aberrations and would
benefit from improved diagnostic subtyping to identify
potential high-risk aberrations.
Methylation of cytosine (5mC) residues in CpG dinu-
cleotides is an epigenetic modification that plays a
pivotal role in the establishment of cellular identity by
influencing gene expression [7,8]. There are approxi-
mately 28 million CpG sites in the human genome that
are targets for DNA methylation. The pathogenesis and
phenotypic characteristics of leukemic cells are partially
explained by specific and genome-wide alterations in
DNA methylation [9-17]. We and others have previously
observed a strong correlation between cytogenetic
subtype and DNA methylation in ALL, which indicates
that DNA methylation profiling may serve as a proxy for
cytogenetic analysis [11,12,14,18].
Herein, we used our previously published 450 k DNA
methylation profiling dataset [14] from >500 primary
ALL samples comprising eight known recurrent sub-
types of ALL to design and evaluate DNA methylation
classifiers for subtype prediction. Using extensive cross-
validation and methylation-based subtyping in an inde-
pendently derived set of ALL patient samples, we show
that DNA methylation classification is a highly sensitive
and specific method for ALL subtyping. Finally, we
aimed to ascertain subtype membership of 210 ALL
patients where no subtype information is available and
verified the DNA methylation-based subtype predictions
with copy number analysis and detection of fusion
genes. The classifier and code required for DNA methy-
lation classification can be freely downloaded at https://
github.com/Molmed/Nordlund-ALL-subtyping.Results
Prediction of ALL subtypes using DNA methylation
classifiers
We previously analyzed the genome-wide DNA methyla-
tion patterns of 756 primary ALL patients diagnosed
between 1996 and 2008 in the Nordic countries [14].
Criteria for selecting patients with established subtypes
for the current study included abnormal karyotypes from
chromosome banding and/or positive results from tar-
geted FISH or RT-PCR analyses. An overview of the pa-
tients included in the study can be found in Additional
file 1: Figure S1. In total, 546 patients fulfilled these cri-
teria and were included in the design of the DNA methy-
lation classifier (Table 1, Additional file 2: Table S1). We
designed DNA methylation classifiers for the following
eight subtypes: T-ALL and the B-cell precursor ALL
(BCP-ALL) subtypes HeH, t(12;21), 11q23/MLL, t(1;19),
dic(9;20), t(9;22), and iAMP21. We also included a clas-
sifier for normal blood cells and patient sex to highlight
samples with low blast count and to verify the sex of
the patients, respectively. We evaluated the perform-
ance of the classifier design procedure by cross-
validation (Additional file 1: Figures S2–S3). The best
performance in terms of sensitivity and specificity was
obtained using a set of 246 consensus CpG sites that
contained 14-42 CpG sites per ALL subtype (Additional
file 1: Figure S4, Additional file 2: Table S2). During
cross-validation, on average, 91% of the ALL samples
were assigned to one single correct subtype, 3.4% were
assigned to multiple subtypes including the correct
subtype, and 5.6% were assigned to an incorrect or no
subtype (Table 2). When the consensus classifier was
trained on the entire data set, it correctly classified 526
out of the 546 samples (95% CI = 515–532 patients).
The consensus classifier failed to predict a subtype for
as few as 17 patients in the design set, and of these pa-
tients, only three were assigned to have an unexpected
subtype (Figure 1A, Additional file 2: Table S1).
All patients with the iAMP21 subtype (n = 8) displayed
high prediction scores according to both the iAMP21
Table 2 Performance of classifiers designed using ALL samples with known subtype
Subtype group Mean sensitivity ± SD Mean specificity ± SD Min CpGs (N)a Max CpGs (N)a Consensus CpGs (N)b
Reference 1.00 ± 0.01 0.99 ± 0.01 13 21 17
T-ALL 0.99 ± 0.02 1.00 ± 0.00 7 17 14
HeH 0.94 ± 0.04 0.95 ± 0.02 23 55 34
t(12;21) 0.97 ± 0.04 0.99 ± 0.01 28 2 263 42
11q23/MLL 0.95 ± 0.11 1.00 ± 0.00 16 27 28
t(1;19) 0.91 ± 0.13 1.00 ± 0.00 9 30 21
dic(9;20) 0.78 ± 0.16 0.99 ± 0.01 24 35 37
t(9;22) 0.70 ± 0.25 0.99 ± 0.01 17 41 23
iAMP21 0.81 ± 0.35 1.00 ± 0.00 11 19 16
Sex 0.98 ± 0.01 1.00 ± 0.01 8 12 14
aThe minimum and maximum number of CpG sites chosen by each subtype classifier during cross validation.
bThe number of CpG sites chosen for each subtype in the consensus classifier.
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HeH obtained a high score in the iAMP21 classifier.
Twenty-six out of 34 (76%) of the consensus CpG sites
in the HeH classifier were hypomethylated in the
iAMP21 samples at similar levels as in the HeH sam-
ples (mean β-value iAMP21 = 0.36 and HeH = 0.28,
Additional file 2: Table S2). The majority of the consen-
sus sites for HeH were hypermethylated across all the
other ALL subtypes (mean β-value >0.77) (Figure 1B).0.0 0.2 0.4 0.6 0.8 1.0
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Figure 1 Prediction of ALL subtypes by consensus CpG sites defined
probability scores of the 546 patients used to design the classifier. Subtype
range from 0 to 1, where a score >0.5 is considered a positive classification
proportions on the right side of the panel give the number of patients acc
samples of known subtype and 139 non-leukemic reference samples accor
sites. Samples are clustered along the horizontal axis and the consensus CpG
low, yellow indicates intermediate, and red indicates high methylation levels.It is likely that the consensus classifier for HeH fails to
exclude sites where iAMP21 is similar to HeH due to
the small number of iAMP21 patients in our study.
Furthermore, gains of chromosome 21 are observed in
both the iAMP21 and HeH subtypes. Nearly 90% (168/
189) of HeH patients have one or more extra copy of
chromosome 21, and thus iAMP21 and HeH may share
some common biological features due to the increased
gene dosage on 21q. Of note, the 10% of atypical HeH546 ALL and 139 reference samples
reference
T−ALL
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using ALL samples of known subtype. (A) The estimated subtype
probability scores are plotted along the horizontal axis. The scores
. The patients are color coded by subtype along the vertical axis. The
urately classified by subtype. (B) Hierarchical clustering of 546 ALL
ding to the methylation levels of the 232 autosomal consensus CpG
sites are clustered along the vertical axis. In the heatmap, blue indicates
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determined by chromosomal banding at diagnosis, were
all accurately classified as HeH.
Blinded validation of ALL subtype classifiers
For independent validation of our DNA methylation
classifiers, 39 newly diagnosed ALL patient samples
that were not included in the classifier design were
analyzed using the 450 k BeadChip (Illumina Inc., San
Diego, CA, USA) and subjected to blinded classifica-
tion. In total, 36 of the 39 (92%) samples were classified
correctly (Figure 2). Review of the clinical diagnosis of
the three misclassified samples revealed atypical results
in the original chromosomal analyses performed at
diagnosis (see Additional file 2: Table S3 for detailed
information).
Classification of ALL samples with unknown cytogenetic
risk group
We performed DNA methylation-based subtype classifi-
cation of 210 BCP-ALL patient samples with no result
(n = 18), normal (n = 87), or non-recurrent karyotype
(n = 105) (Figure 3A). In total, 106 of the 210 samples
were assigned to one of the recurrent subtypes with an
estimated class probability of ≥0.50 (Figure 3B). Because
all the iAMP21 patients obtained high scores from both
the iAMP21 and HeH classifiers in the design set, we
counted all patients with this pattern as iAMP21 only.
In total, we assigned a subtype to 50 out of 105 patients
in the non-recurrent group, 50 out of 87 patients in theT-
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Figure 2 Subtype prediction of 39 independent validation ALL
samples. Each sample in the validation set is represented as a
vertical bar positioned in its corresponding subtype as indicated
below the horizontal axis. The color key to the right of the panel
shows the estimated subtype probability. A value >0.5 indicates high
probability of correct classification. Subtype probability scores <0.5 are
not shown.group with normal karyotype, and 13 out of the 18 pa-
tients in the group with no cytogenetic results available
(Additional file 2: Tables S4–S6). The distribution of the
newly assigned patients from the normal karyotype
group and group of patients with no cytogenetic results
was as could be expected in a pediatric ALL population
(Figure 3C). The methylation profiles of the newly
classified samples closely matched those of the group of
original samples used to design the classifier and are
referred to as ‘subtype-like’ (Figure 3D, Additional file 1:
Figures S5–S12).
A small group of 17 patients classified into two or
more groups and are denoted as ‘multi-class’. The most
common ‘multi-class’ subtype was double classification
as dic(9;20) and t(9;22). Eighty-three patients (~10% of
the entire cohort) did not have methylation patterns that
are similar to any of the subtype groups, and they were
labeled as ‘non-class’. Four patients received high scores
in the classifier for non-leukemic reference samples and
were excluded from further analysis. According to hier-
archical clustering, the patients in the ‘multi-class’ group
displayed variable degrees of hypomethylation in the dic
(9;20) and t(9;22) consensus CpG sites, which is in
agreement with double classification in those subtype
groups (Figure 3E, Additional file 1: Figure S13). The
‘non-class’ patients separated into three clusters and did
not display strong similarities to any of the other known
ALL subtypes.
Subtype verification
Verification by karyotype
All patients in the group with non-recurrent aberrations
(n = 105) had information from karyotyping performed
at diagnosis (Additional file 2: Table S7). We used this
information to provide support for the DNA methylation
classification (Table 3). Nine out of ten patients with
HeH-like methylation profiles had gains of chromosome
21, six of them had 48–49 chromosomes, and three had
Down's syndrome (constitutional + chr21). This finding
indicates that the methylation status of the genes in the
HeH classifier is associated with chromosomal aneu-
ploidy. Thus, these patients may share common bio-
logical features although they do not have the >50
chromosomes, which is the criteria used to define HeH
as a subtype. All iAMP21-like patients (n = 4) and the
single patient classified as 11q23-like had aberrations
suggestive of, but not conclusive for, the canonical rear-
rangements in their karyotype data.
Verification by expressed fusion genes
Targeted analysis using FISH or RT-PCR for ETV6/
RUNX1, MLL rearrangements, PBX1/TCF3, and BCR/
ABL1 had been performed for only 57% of the subtype-
like patients at the time of diagnosis. Therefore, it is
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Figure 3 Classification of ALL samples with undefined cytogenetic subtypes. (A) Each sample (n= 210) is represented as a vertical bar positioned
in its corresponding subtype ‘track’ according to its allocation by the classifier. The color key to the right of panel (A) shows the estimated subtype
probability scores. Probability scores <0.5 are not shown. (B) The distribution of probability scores ≥0.5 in the 210 patients. Eighty-three patients were
not classified, 106 patients were unequivocally assigned to one subtype, 17 patients were classified into multiple subtype groups, and four patients had
high reference scores. (C) The distribution of the number of patients with ‘normal’, ‘no result’, and ‘non-recurrent’ karyotypes into subtype-groups. The
subtype distribution in the known sample group is also shown. (D) Hierarchical clustering of the original 546 ALL patients of known subtype and the
patients newly classified as one unequivocal subtype (n = 106). Patients are clustered on the horizontal axis and the 215 autosomal subtype-specific
consensus CpG sites are clustered on the vertical axis and color-coded by subtype classifier. The darker color indicates samples with previously
established cytogenetic subtype, and the corresponding lighter color and asterisk (*) indicates newly classified samples. The color key for the
patient samples is shown to the left of the heatmap. In the heatmap, blue indicates low and red indicates high methylation levels. (E) Hierarchical
clustering and heatmap of the ALL patients of known subtype (n = 546), those newly classified and unequivocally assigned to one subtype (n = 106),
patients without classification (n = 83, gray), and patients classified into multiple subtypes (n = 17, black). Four patients with suspected low blast count
are not shown.
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harbor the canonical translocations that define the group
they were assigned to by our DNA methylation classifier.
Re-analysis by RT-PCR for the ETV6/RUNX1 fusion
transcript in RNA taken at diagnosis from eight ran-
domly selected t(12;21)-like patients with available RNA
showed that half of them were positive for ETV6/
RUNX1 (Additional file 2: Table S8).
We performed RNA-seq of 17 patients with available
high quality RNA for whom cytogenetic subtype infor-
mation from ALL diagnosis and the results obtained by
the DNA methylation classifier did not agree. In nine
out of these 17 patients, we detected expressed fusion
genes (Table 4, Additional file 2: Table S9). Three previ-
ously unknown fusion genes t(20;21)RUNX1/ASXL1,
t(7;12)ETV6/CBX3, and t(3;12)ETV6/AK125726 were
identified in patients with t(12;21)-like methylation pro-
files. We found that several of the patients assigned toTable 3 Summary of subtype verification results
Methylation
subtype
Confirmed subtypea Subtype-lik
N Karyotyped RT-PCRe CNAf N
T-ALL* 0/1 (0%) 0 ND ND 0/1 (0%)
HeH* 7/25 (28%) 0 ND 7 18/25 (72%)
t(12;21)* 4/33 (12%) 1 4 ND 22/33 (67%)
11q23/MLL* 3/4 (75%) 1 ND 3 1/4 (25%)
t(1;19)* 0/15 (0%) 0 ND ND 9/15 (60%)
dic(9;20)* 3/19 (16%) 0 ND 3 16/19 (84%)
t(9;22)* 0/5 (0%) 0 ND ND 3/5 (60%)
iAMP21* 4/4 (100%) 4 ND 4 0/4 (0%)
*DNA methylation-based subtype group. Asterisks indicate groups classified by DNA
aNewly classified patients with confirmed verification of their subtype group by at l
bNewly classified patients negative for the canonical event that defines their subtyp
cNewly classified patients without a positive or negative result from one of the veri
dNumber of patients with a chromosomal aberration observed in karyotyping result
eNumber of patients positive for respective fusion genes by re-analysis by RT-PCR.
fThe number of patients with chromosomal aberrations discovered by array-based c
gThe number of subtype-like patients negative for canonical aberrations by targete
hThe number of patients with novel (non-canonical) fusion genes detected.
Abbreviations: NA not applicable, ND not determined.the ‘multi-class’ group according to the DNA methyla-
tion classifier harbored fusion genes with PAX5 as one
of the fusion partners, including the known t(9;12)
PAX5/ETV6 and inv(9p13.2)PAX5/ZCCHC7 fusion genes
previously reported in ALL [19-21]. We also identified
a new fusion gene, t(9;14)PAX5/ESRRB, which to our
knowledge has not been previously reported. In an in-
fant patient with HeH in the validation cohort who was
misclassified as ‘non-class’ (ALL_validation_20 in Table 4),
we identified an additional novel fusion gene, t(5;15)
BRD9/NUTM1.
Verification by copy number analysis
Since the 450 k BeadChip assay uses the same reaction
principle as SNP genotyping arrays, the 450 k data can
be used to detect copy number alterations (CNAs)
[22-24]. CNA analysis was applied to identify large-scale
chromosomal gains and losses to support the subtypeeb Unconfirmed
subtypec
Karyotyped Negative for
fusion geneg
Novel fusion
geneh
CNAf N
0 NA ND ND 1/1 (100%)
8 NA ND 13 0/25 (0%)
0 19 3 ND 7/33 (21%)
0 1 ND ND 0/4 (0%)
0 9 0 1 6/15 (40%)
5 NA 0 10 0/19 (0%)
0 3 ND ND 2/5 (40%)
0 NA ND ND 0/4 (0%)
methylation.
east one verification method.
e and/or non-canonical event.
fication methods.
s determined at diagnosis in NOPHO centers.
opy number alteration (CNA) that support subtype classification.
d analyses (FISH/RT-PCR) at diagnosis.
Table 4 Fusion gene screening by RNA sequencing
Sample ID Subtype Methylation subtypea FISH/PCR Read pairs Fusion gene
ALL_176 Non-recurrent t(1;19)* t(1;19) Not tested 84.3 M No fusion detected
ALL_392 Normal t(1;19)* t(1;19) Negative 94.4 M No fusion detected
ALL_390 Normal t(1;19)* t(1;19) Negative 102.6 M No fusion detected
ALL_11 No result t(12;21)* t(12;21) Not tested 99.5 M t(20;21)RUNX1/ASXL1
ALL_106 HeH t(12;21)* t(12;12) Negative 57.3 M t(7;12)CBX3/ETV6
ALL_495 Normal t(12;21)* t(12;21) Negative 32.1 M t(3;12)ETV6/AK125726
ALL_391 Non-recurrent dic(9;20)* NA 98.6 M No fusion detected
ALL_58 Non-recurrent Non-class NA 89.0 M No fusion detected
ALL_61 Normal Non-class NA 101.8 M No fusion detected
ALL_Validation_20 HeH Non-class NA 19.0 M t(5;15)BRD9/NUTM1
ALL_313 Non-recurrent Multi-class NA 116.7 M No fusion detected
ALL_619 Non-recurrent Multi-class NA 84.3 M t(9;14)PAX5/ESRRB
ALL_403 Non-recurrent Multi-class NA 95.2 M inv(9)PAX5/ZCCHC7
ALL_246 Non-recurrent Multi-class NA 120.5 M t(9;12)PAX5/ETV6
ALL_485 Non-recurrent Multi-class NA 90.6 M t(9;12)PAX5/ETV6
ALL_373 Non-recurrent Multi-class NA 96.2 M del(X)P2RY8/CRLF2
ALL_497 Non-recurrent Multi-class NA 89.7 M No fusion detected
*Patients with DNA methylation patterns similar to those of the recurrent ALL subtypes.
aSubtype determined by DNA methylation-based classification.
Abbreviation: NA not applicable.
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patients, in whom unbalanced large scale chromosomal
alterations are expected to occur, such as in HeH, t
(1;19), dic(9;20), and iAMP21 (Table 3, Additional file 2:
Table S7).
We observed >50 chromosomes in six out of 15 of the
HeH-like patients with ‘normal’ or ‘no result’ in the
karyotype analysis, suggesting that these patients did in
fact harbor aneuploidies that were undetected at diagno-
sis (Additional file 1: Figure S14). We also found evi-
dence for amplification of chromosome 21q, which is
consistent with the iAMP21 subtype in each of the four
iAMP21-like patients (Additional file 1: Figure S15). In
three out of the 21 dic(9;20)-like patients and in one
multi-class patient, we found deletions of chromosome
9p and 20q, which confirm that these four patients
harbor dic(9;20). Thirteen out of the 20 remaining dic
(9;20)-like patients and 11 out of the 17 ‘multi-class’
patients displayed deletions of various sizes on 9p but
lacked 20q deletions (Additional file 1: Figure S16).
We found a breakpoint in the TCF3 locus in one of
the t(1;19)-like patients (Additional file 1: Figure S17).
The remaining 18 t(1;19)-like patients showed no evi-
dence of CNAs on chromosomes 1 or 19, which does
not exclude that these patients harbor balanced translo-
cations, which are common in this subtype. Although
t(9;22) results in a balanced re-arrangement that cannot
be detected by CNAs, we screened the t(9;22)-like pa-
tients for IKZF1 deletions which are known to occur inpatients with the BCR/ABL1 fusion gene and BCR/
ABL1-like gene expression patterns [25]. In three out of
the five t(9;22)-like patients, we detected intragenic
IKZF1 deletions or iso(7q), resulting in hemizygous loss
of IKZF1 (Additional file 1: Figure S18).
Clinical outcome of the newly classified ALL patients
The clinical features of the newly classified patients, in-
cluding age, white blood cell count at diagnosis, central
nervous system involvement, and outcome were similar
to those of the original patients with known subtypes
(Table 5). No significant differences in the cumulative
incidence of relapse were detected between the newly
classified and previously established patient groups
(Additional file 1: Figures S19–S20). The multi-class
group had an overall favorable prognosis (one relapse in
17 patients), despite the fact that the patients in this
group had a median age of diagnosis of 10 years.
Down's syndrome ALL
Nineteen BCP-ALL patients with Down's syndrome
(DS-ALL) were included in our study. These patients
were not classified separately from ALL patients without
DS. Two DS-ALL patients had t(12;21) and one had t
(9;22). Each of these three patients was classified cor-
rectly according to their cytogenetic subtype. Eight
DS-ALL patients had the karyotype ‘other’, seven had a
‘normal’ karyotype, and one had ‘no result’. Only four of
the DS-ALL patients were classified as HeH-like, and
Table 5 Clinical characteristics of ALL patients of known and newly classified subtype
Subtype N (%)a Sex
M:F
Age
median
(range)
WBC
median
(range)
CNS,b
n/y/u
CIRc NOPHO protocold EsPhALLe Infantf Other/
NAgSR IR HR Ph+
T-ALL 101 (0.18) 2.9 9 (1–17) 138 (1–788) 89/12/0 0.20 0 2 86 1 0 0 12
T-ALL* 1 (0.00) NA 11 (NA) 2 (NA) 1/0/0 0.00 0 0 1 0 0 0 0
HeH 189 (0.35) 1.2 3 (1–17) 9 (0–131) 187/2/0 0.16 82 79 22 0 0 0 6
HeH* 25 (0.12) 2.1 4 (1–14) 9 (1–91) 24/1/0 0.28 8 10 3 0 0 0 4
t(12;21) 161 (0.29) 1.1 4 (1–15) 14 (1–226) 159/0/2 0.22 68 65 24 0 0 0 4
t(12;21)* 33 (0.16) 1.1 4 (0–15) 11 (1–136) 33/0/0 0.24 12 11 6 0 0 1 3
11q23/MLL 27 (0.05) 0.7 0 (0–15) 193 (2–986) 25/1/0 0.41 0 1 11 0 0 14 1
11q23/MLL* 4 (0.02) 4.0 1 (0–1) 81 (38–1,255) 4/0/0 0.50 0 1 2 0 0 1 0
t(1;19) 21 (0.04) 0.8 11 (1–15) 35 (6–159) 20/1/0 0.14 0 3 17 0 0 0 1
t(1;19)* 15 (0.07) 0.9 7 (1–15) 10 (5–222) 14/1/0 0.07 1 9 3 0 0 0 2
dic(9;20) 20 (0.04) 0.4 2 (1–15) 50 (4–336) 19/1/0 0.25 4 5 10 0 0 0 1
dic(9;20)* 19 (0.09) 1.7 4 (1–18) 12 (1–164) 19/0/0 0.21 3 11 2 0 0 0 3
t(9;22) 19 (0.03) 2.2 10 (2–14) 61 (3–246) 17/2/0 0.47 0 0 1 6 12 0 0
t(9;22)* 5 (0.02) 4.0 12 (4–15) 102 (13–146) 5/0/0 0.40 0 0 1 0 0 0 4
iAMP21 8 (0.01) 7.0 9 (5–17) 5 (2–62) 8/0/0 0.38 2 3 1 0 0 0 2
iAMP21* 4 (0.02) 0.3 9 (7–16) 9 (4–23) 4/0/0 0.50 1 2 0 0 0 0 1
Multi-class 17 (0.03) 0.9 10 (3–17) 23 (1–106) 16/1/0 0.06 1 6 2 0 0 0 8
Non-class 83 (0.15) 1.5 9 (0–18) 20 (1–274) 80/3/0 0.23 13 30 25 0 0 3 11
*Patients with subtype determined by DNA methylation-based classification.
aProportion of the total number of patients in the known subtype groups (n = 546) and newly classified patients (n = 210).
bCentral nervous system involvement.
cCumulative incidence of relapse (relapse as event of interest and other events as censoring).
dNumber of patients treated on NOPHO-ALL treatment protocols.
eNumber of patients treated according to the EsPhALL protocol.
fNumber of patients treated according to the Interfant-99 or Interfant-06 protocols.
gNumber of patients treated on other protocol or information not available.
Abbreviations: WBC white blood cell count at diagnosis, n/y/u no/yes/unknown, SR standard risk, IR intermediate risk, HR high risk, Ph + Philadelphia positive.
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diagnosis by chromosomal banding or array-based CNA
detection. The chromosomal gains included +14, +17,
and + X, which are the typical chromosomal gains ob-
served in HeH in addition to +21c. Additional details
about the classification of DS-ALL patients can be found
in Additional file 2: Table S7.
Annotation of the consensus CpG sites in the ALL
subtype classifier
Remarkably, none of the consensus CpG sites in the
classifier were located in the genomic regions harboring
the subtype-specific cytogenetic aberrations. For ex-
ample, none of the consensus CpG sites for the iAMP21
subtype were located on chromosome 21, none of the
CpG sites for the t(12;21) subtype were located on chro-
mosomes 12 or 21, and none of the CpG sites defining
the 11q23/MLL, dic(9;20), and t(1;19) subtypes were on
chromosomes 11, 9, 20, 1, or 19, respectively.
Over 90% of the consensus CpG sites for each the BCP
ALL subtypes were hypomethylated (median β-value 0.19)
in the patients belonging to the respective subtypes, whileall other patients were highly methylated. The CpG sites
in the T-ALL classifier were hypermethylated in T-ALL
patients (median β-value 0.92) and hypomethylated in the
BCP ALL patients (median β-value 0.04). Over 95% of the
consensus CpG sites were annotated to protein coding
genes, and the majority (87%) of them were located out-
side CpG islands (Additional file 2: Table S2). Several of
the genes highlighted in our classification procedure are
associated with a somatic mutation or differential DNA
methylation or gene expression patterns in ALL subtypes
such as DDIT4L(4q23) in HeH [14,26], CBFA2T3(16q24),
TCFL5(20q13.33), DSC3(18q12.1), and EPOR(19p13.3-
p13.2) in t(12;21) [12,14,25-29], MBNL1(3q25) and ZEB2
(2q22.3) in 11q23/MLL [25,30], and NT5C2(10q24.32)
and PON2(7q21.3) in t(9;22) [26,27,31,32]. However, most
of the genes that we identified with CpG methylation that
was characteristic of specific ALL subtypes have no previ-
ously known function or connection with ALL.
Discussion
We present a method for the identification of recurrent
cytogenetic abnormalities in patients with ALL using
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sifier that consists of only 246 CpG sites is able to accur-
ately detect the subtype of primary ALL samples. Nearly
50% of 210 ALL patients in our study that had not previ-
ously been assigned to a recurrent subtype group at
diagnosis displayed DNA methylation patterns that are
similar to those of the eight recurrent subtypes of ALL
investigated in the present study. Thus, DNA methyla-
tion analysis could complement current cytogentic and
molecular biological analyses applied in routine diagno-
sis of ALL to allow stratification of a larger number of
ALL patients into risk-based treatment groups. Verifica-
tion of our DNA methylation-based analyses suggests
that at least 21 out of the 106 patients classified by DNA
methylation harbor one of the canonical aberrations that
define an ALL subtype, which were not detected at the
time of diagnosis. Since our cohort of ALL patients in-
cluded samples diagnosed as early as 1996, the fact that
the canonical aberrations were not detected at diagnosis
could be due to technical limitations of the methods ap-
plied at that time.
In contrast to traditional methods used for diagnostics,
which require >1 ug of RNA or intact dividing cells,
analysis of DNA methylation using the 450 k BeadChip
requires only 250 ng of DNA, which is useful for cases
where little material is available, especially for biobanked
samples. A more targeted diagnostic test than the 450 k
BeadChip could be constructed for routine use to
analyze the limited number of CpG sites that constitutes
the classifier. On the other hand, the use of the 450 k
BeadChip could be an advantage as the CpG site content
of the classifier might be altered when novel ALL
subtypes have been defined.
In our study, we found several new fusion genes in
subtype-like patients that involve the same chromosomes
and genes as the known fusion genes that define the
known subtypes of ALL, which appear to result in the
similar DNA methylation patterns. The patients harboring
non-canonical gene fusions include ETV6, RUNX1, or
PAX5. This observation indicates that alterations that
affect either one or both of the gene fusion partners may
influence the DNA methylation patterns of the CpG sites
in our classifier. The newly identified fusion genes in pa-
tients with t(12;21)-like methylation profiles include
CBX3/ETV6, and RUNX1/ASXL1, and notably both CBX3
and ASXL1 are known to be mutated in ALL and in AML,
respectively [31,33]. Furthermore, the patients that we
classified into multiple subtype groups display the previ-
ously unreported PAX5/ESRRB fusion gene and the
PAX5/ZCCHC7 and PAX5/ETV6 fusions that occur in
approximately 1% of ALLs [19-21]. The high prevalence of
PAX5 fusions in this group raises the question of whether
these patients comprise a biologically and clinically dis-
tinct subgroup. We also discovered an unexpected novelfusion gene involving BRD9/NUTM1 in an infant patient
with HeH who did not classify into any subtype group.
BRD9 is required for the oncogenic properties of the
MLL-fusion proteins [34], which are common in infant
ALL patients. A similar fusion gene, BRD4/NUTM1, de-
fines a lethal subtype of midline carcinoma [35,36]. These
observations warrant further investigation in additional
pediatric ALL patients to determine their prognostic or
potential therapeutic value.
The translocations resulting in the expression of a
fusion protein may modulate DNA methylation patterns
via aberrant repression or activation of downstream
genes. This hypothesis is supported by the observation
that the majority (85%) of CpG sites in the consensus
classifier are hypomethylated, by previous reports of
aberrant gene expression in the subtype for which they
were selected [14,18,25-28], and because the subtype-
specific sites are spread out across all autosomes and are
not clustered near the physical translocation break-
points. One patient (Validation_ALL_39) was positive
for t(1;19) with FISH and negative for expression of
TCF3/PBX1 due to deletion of the TCF3 gene in the
translocation. Consequently, this patient failed to classify
as a t(1;19). The alteration of gene expression cascades
due to the activity of the fusion proteins may be essen-
tial for the DNA hypomethylation pattern in patients
with t(1;19) and the other translocations, which presum-
ably occur in the early stages of leukemic transformation
and are maintained through cellular division and clonal
evolution.
The reason behind the striking similarities in DNA
methylation in patients with HeH remains a mystery. Be-
cause the DNA methylation profiles are so similar in pa-
tients harboring various combinations of chromosomal
gains, the methylation changes may predate the gains in
chromosome number. Yeoh and colleagues reported that
most of the genes whose expression patterns define HeH
are on chromosomes 21 or X [28]. Although we did not
analyze the X chromosome due to its inactivation in
females, the consensus CpG sites for HeH were distrib-
uted across the different autosomes and only two of the
CpG sites were on chromosome 21. One of them was in
the CLDN14 gene in the Down's syndrome breakpoint
region, and the second CpG site was located in a non-
coding RNA gene on 21q22.3. Our results indicate that
the HeH-like patients with 47–50 chromosomes are a
biological group with similar etiology and clinical out-
come as those with >50 chromosomes. As more ALL ge-
nomes are sequenced, it will be interesting to see if there
are recurrent somatic mutations and/or cryptic genomic
rearrangements that provide a unifying cause underlying
the HeH subtype.
We recognize that several more recently identified
subtypes characterized by additional aberrations of IKZF1
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translocations involving tyrosine kinase genes were not
included in the present study [1,2,37]. The prevalence of
such aberrations is under investigation in Nordic ALL
patients [38,39]. When these data become available, it will
be possible to determine if the patients harboring these
aberrations form distinct subgroups based on their DNA
methylation profiles.
Conclusions
Together with response to induction therapy, genetic
aberrations are among the most important prognostic
factors in pediatric ALL. Our findings indicate that DNA
methylation profiling can contribute to reduction of the
heterogeneity in undefined ALL patient groups and can
potentially be implemented for diagnostics of ALL and
possibly other types of hematological cancers. Follow-up
studies of findings where DNA methylation and cytogen-
etic aberrations do not agree provide an interesting
approach for the discovery of previously unrealized
chromosomal aberrations in ALL. Annotation of the
CpG sites that constitute the subtype classifier highlights
genes that are known to be relevant for ALL, which
suggests a functional role for methylation of these sites
but also genes with no known function in ALL are
highlighted for further studies.
Methods
Clinical diagnostic analysis of ALL samples
Bone marrow aspirates or peripheral blood samples were
collected at diagnosis from 756 population-based
pediatric ALL patients enrolled between 1996 and 2010
on the Nordic Society of Pediatric Hematology and On-
cology (NOPHO), EsPhALL, or Infant treatment proto-
cols (Additional file 2: Table S10) [4,40,41]. Diagnoses
were established by analysis of leukemic cells with re-
spect to morphology, immunophenotype, and cytogenet-
ics. HeH was defined as 51–67 chromosomes per cell
[42]. FISH or RT-PCR analyses were used to screen for
the following translocations: t(12;21)(p13;q22)[ETV6/
RUNX1], t(9;22)(q34;q11)[BCR/ABL1], and t(1;19)(q23;
p13.3)[TCF3/PBX1]. FISH or Southern blot analyses
were used to identify MLL rearrangements, more than
three copies of RUNX1 by FISH define iAMP21, and
high resolution SNP arrays and/or FISH were used to
detect dic(9;20) aberrations [43,44]. The study was ap-
proved by the Regional Ethical Review Board in Uppsala,
Sweden and was conducted according to the guidelines
of the Declaration of Helsinki. The patients or their
guardians provided informed consent.
DNA methylation assay and samples
Genome-wide DNA methylation data for ~450,000 CpG
sites was generated as previously described [14]. A totalof 546 out of 756 patients were determined to have estab-
lished subtype by chromosome banding and/or positive
results from targeted FISH and RT-PCR analyses and were
included in the design of the DNA methylation classifier
(Table 1, Additional file 2: Table S1). Thirty-nine blinded
DNA samples were obtained from newly diagnosed ALL
cases as an independent validation set (Additional file 2:
Table S3). The reference panel for determining samples
with low leukemic blast content consisted of remission
bone marrow aspirates from pediatric ALL patients
(n = 86) and fractionated blood cells from healthy donors
(n = 51) [14].
In total, 210 patients included in the current study did
not belong to one of the canonical subtypes according to
results from chromosomal banding or targeted assays
performed at ALL diagnosis. Patients denoted as ‘non-
recurrent’ harbored non-recurrent aberrations (n = 105,
Additional file 2: Table S4). Patients designated as ‘normal’
(n = 87) displayed normal karyotypes and were negative in
the targeted assays (Additional file 2: Table S5). Patients
designated as ‘no result’ failed in the cytogenetic analysis
(n = 18, Additional file 2: Table S6).
Predictive modeling of ALL subtypes using DNA
methylation
Methylation-based classifiers were designed to distin-
guish between ten pairs of groups: ALL against reference
samples, female against male, and each of the eight
subtypes T-ALL, HeH, t(12;21), 11q23/MLL, t(1;19), dic
(9;20), t(9;22), and iAMP21 against a background of the
other ALL subtypes. The sex classifier was trained on all
chromosomes except Y, and the other classifiers were
trained on autosomes only. The male-versus-female clas-
sifier was implemented to highlight sample mix-ups.
The classifiers were created using Nearest Shrunken
Centroid (NSC) classification [45]. The NSC modeling
procedure consisted of a feature selection step and a
training step (Additional file 1: Figure S2). In the feature
selection step, fivefold cross-validation was repeated five
times. CpG sites selected during the NSC training
process in 17/25 cross validation folds were selected as
‘consensus CpG sites’ (Additional file 1: Figure S3). The
performance of the consensus classifier was evaluated
using external cross-validation (Additional file 1: Figure
S2). Additional details on the classification procedure
can be found in Additional file 1.
Analysis of copy number alterations
CNA data was generated from raw signal intensities ex-
tracted from Genome Studio (Illumina Inc., San Diego,
CA, USA). For each probe, the intensities were summed
(methylated + unmethylated signals) and subjected to
quantile normalization using the preprocessCore pack-
age in R [46]. Log2 ratios were calculated by dividing the
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non-leukemic reference cells. CNAs were detected by
plotting the log2 ratios in the integrative genomics
viewer (IGV) [47].
Analysis of fusion genes
One microgram of total RNA was converted to cDNA
using the Superscript III kit (Life Technologies, Carlsbad,
CA, USA) and subjected to RT-PCR for the fusion tran-
script ETV6/RUNX1 using the probe set ENF301-
ENPr341-ENR361 (Life Technologies, Carlsbad, CA,
USA). Strand-specific RNA-sequencing libraries were
generated from 1 μg total RNA with the ScriptSeq v1.2
kits (Epicentre, Madison, WI, USA), followed by sequen-
cing on a HiSeq2000/2500 or MiSeq instrument (Illumina
Inc., San Diego, CA, USA). Gene fusions were detected
using the FusionCatcher software [48]. Details about the
fusion gene analysis can be found in Additional file 1.
Availability of supporting data
Methylation data are available at the Gene Expression
Omnibus under series GSE49031. The R-code is available
at Github (https://github.com/Molmed/Nordlund-ALL-
subtyping).
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Figures S1–S20.
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